Antiviral Chemotherapy 5

New Directions for Clinical Application and Research

  • John Mills
  • Paul A. Volberding
  • Lawrence Corey

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 458)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Mario G. Pessoa, Teresa L. Wright
    Pages 1-10
  3. Christine M. Hunt, Nathaniel A. Brown, Marc Rubin
    Pages 11-21
  4. Clarence L. Young
    Pages 23-27
  5. Frederick G. Hayden
    Pages 55-67
  6. Jon M. Rogers, Guy D. Diana, Mark A. McKinlay
    Pages 69-76
  7. Sharon Safrin, Julie Cherrington, Howard S. Jaffe
    Pages 111-120
  8. Stephen A. Spector
    Pages 121-127
  9. Jeffrey Chulay, Karen Biron, Laurene Wang, Mark Underwood, Stanley Chamberlain, Lloyd Frick et al.
    Pages 129-134
  10. Stephen L. Sacks, Bruce Wilson
    Pages 135-147
  11. Andrew R. Bell
    Pages 149-157
  12. Richard J. Whitley, John W. Gnann Jr.
    Pages 159-165
  13. Suzanne Crowe
    Pages 183-197
  14. Douglas Richman, Suzanne Crowe, Katya Harvey
    Pages 199-212
  15. Julie Louise Gerberding, Mitchell H. Katz
    Pages 213-222
  16. Lawrence Corey, M. Michelle Berrey
    Pages 223-227
  17. James O. Kahn
    Pages 229-237
  18. Back Matter
    Pages 267-271

About this book


Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in­ cubation period of active HIV infection, when the infection is clinically latent, is now un­ derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re­ sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re­ member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both.


HIV HIV infection Hepatitis infection infections virus

Editors and affiliations

  • John Mills
    • 1
  • Paul A. Volberding
    • 2
  • Lawrence Corey
    • 3
  1. 1.Macfarlane Burnet Centre for Medical ResearchFairfieldAustralia
  2. 2.University of California, San FranciscoSan FranciscoUSA
  3. 3.University of WashingtonSeattleUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media New York 1999
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-7150-2
  • Online ISBN 978-1-4615-4743-3
  • Series Print ISSN 0065-2598
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals